aren't MSB seeking approval from FDA with this?
Mesoblast Chief Medical Officer Dr Fred Grossman said: “We expect the mortality benefit observed in
this seminal Phase 3 trial will support a potential path for approval of rexlemestrocel-L in patients with
advanced chronic heart failure. We are planning to meet and discuss potential pathways to approval
based on mortality reduction with the United States Food and Drug Administration.”
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 Chronic Heart Failure Results
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-166
-
-
- There are more pages in this discussion • 857 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
90.0¢ |
Change
-0.015(1.64%) |
Mkt cap ! $1.044B |
Open | High | Low | Value | Volume |
90.5¢ | 90.5¢ | 89.5¢ | $678.5K | 753.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 950486 | 89.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
90.0¢ | 20432 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 936880 | 0.895 |
18 | 121530 | 0.890 |
6 | 125494 | 0.885 |
13 | 297067 | 0.880 |
5 | 561007 | 0.875 |
Price($) | Vol. | No. |
---|---|---|
0.900 | 27176 | 11 |
0.905 | 38019 | 4 |
0.910 | 57504 | 4 |
0.915 | 26947 | 4 |
0.920 | 50423 | 3 |
Last trade - 10.22am 08/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |